This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABT-555

AbbVie Inc.

Drug Names(s): ABT555, ABT 555

Description: ABT-555 is a monoclonal antibody, under development by AbbVie targeting RGMa for the treatment of multiple sclerosis and spinal cord injury.


ABT-555 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug